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with severe heart failure (HF) in the COPERNICUS study, of whom 132 had a SBP of 85- 
95 mm Hg and 264 had a SBP of 96-105 mm Hg at the time of randomization. Following 
initiation of treatment, SBP increased (CRV>PBO) in the patients with low SBP and fell 
transiently (CRV>PBO) in the patients with higher SBP. Results (see table): 
All-Cause Mortality Death or HF Hospitalization 
1-year PBO Hazard ratio 1-year PBO Hazard ratio 
rate (CRV:PBO) rate (CRV:PBO) 
85-95 mm Hg 34% 0.77 61% 0.74 
96-105 mm Hg 25% 0.61 43% 0.75 
106-115 mm Hg 18% 0,65 37% 0.78 
116-125 mm Hg 17% 0.61 40% 0.54 
> 125 mm Hg 15% 0.60 32% 0.68 
Patients with low baseline SBP were at extremely high risk of a major clinical event, the 
magnitude of risk decreasing with increasing SBP. However, CRV decreased the risk of 
death and of death or HF hospitalization in all SBP subgroups, the magnitude of benefit 
being independent of SBP (interaction P=0.64 and P=0.80 for mortality and for death or 
HF hospitalization, respectively). The rate of permanent withdrawal decreased with 
increasing baseline SBP (P=0.0001), similarly for PBO and CRV (interaction P=0.25). 
Hypotension was reported as an adverse effect more with CRV than PBO overall; this dif- 
ference was not accentuated in the low SBP subgroups. 
Conclusions. These results provide the first evidence that CRV is effective and wen toler- 
atsd in patients with severe HF and a low SBP. 
4:45 p.m. 
839-4 The Carvedl lo l  Hibernation Reversible Ischemia Trial: 
Marker of Success (CHRISTMAS) 
John G. Cleland. D. J. Pennell, S. G. Ray, A. J. Coats, A. Lahiri, P. W, Macfarlane, J. 
Dalle Mule, Z. Vered, G. Murray, for the CHRISTMAS Investigators, Castle Hill Hospital, 
Kingston Upon Hill, United Kingdom. 
Background: Improved left ventitcular ejection fraction (LVEF) in response to beta-block- 
ers is a consistent finding in dilated cardiomyopathy while it is less consistent in 
ischaemic heart disease (IHD). This heterogeneous response could be explained by the 
volume of hibernating mycoardium or of scarred myocardium. 
Methods: Patients with chronic heart failure (HF) of ischaemic etiology and left ventricular 
systolic dysfunction (wall motion (WM) index _< 1.3 by echcoardiography, corresponding 
to a LVEF -< 39%) were enrolled in this international double-blind randomised trial. The 
primary objective was to determine whether the presence of hibernating myocardium 
predicted the magnitude of improvement in LVEF in response to carvedilol or placebo. 
Myocardial status (hibernating or non-hibernating) was assessed by correlating the 
echocardiographic WM findings to the results of myocardial perfusion imaging (MPI). 
Hibernation was defined as a regional mismatch between impaired WM with preserved 
myocardial perfusion by MPI. Baseline LVEF was assessed by radionuclide ventdculog- 
raphy (RNVG). Echocardiographic and nuclear studies were blindly assessed by core 
laboratories. Hibernators and non-hibernators were stratified into two treatment groups of 
similar size, randomised to carvediloJ or placebo, and titrated up to 25 mg bid. The total 
duration of the trial was about 6 months. 
Results: 305 patients were included in the analysis: 90% males (mean age 62 years), 
73% angina-free during daily activity, 60% in NYHA class II, 29% in class IlL Mean base- 
line LVEF was 29 ± 11% (SD). 181 (59%) were classified as hibernators. LVEF was 
unchanged after 6 months in patients on placebo regardless of myocardial status. Both 
the hibernating and non-hibemating groups showed significant LVEF improvement with 
carvedilol. Within the carvedilol group, patients with lower LVEF and larger volumes of 
hibemating myocardium had a greater LVEF response. 
Conclusion: These data suggest that some of the effect of carvedilol on LVEF may be 
mediated through improvement of hibernating myocardium. Medical therapy may be an 
important adjunct or alternative to revascularisation for patients with hibernating myocar- 
dium. 
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Background: ACE-inhibitors (ACE-i) reduce mortality and morbidity in lots with chronic 
heart failure (CHF). Nonetheless, nearly 20% of potentially eligible pts may not be pre- 
scribed on ACE-i. 
Aim: To evaluate the effects of the angiotensin II receptor blocker (ARB) valsartan (V) in 
the pts randomized in the VaI-HeFT trial not receiving ACE-inhibitors. 
Methods and Results: VaI-HeFT was an international, randomized, double-blind trial test- 
ing V vs placebo (P) when added to the prescribed treatment of pts with CHF. The two 
primary end points were all-cause mortality and morbidity defined as all-cause deeth. 
resuscitated sudden death, hospitaJization for CHF, or administration of iv inotropes or 
vasodilatore for >= 4h without hospitalization. Of the 5010 pts enrolled in the tdal, 366 
(9.3%) were not treated with ACE-i at baseline, but 39% were on betablcokers. Pts 
already on treatment with an ARB were excluded. Baseline characteristics and concomi- 
tant treatments were comparable in V and P groups not taking ACE-i. Analysis of covari- 
ance was performed to assess the effect of V in this subgroup (Table). 
Conclusion: VaI-HeFT has provided the first placebo-controlled outcome data demon- 
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strating a favorable effect of an ARB on mortality and morbidity in pts with CHF not 
treated with ACE-L The improved left ventricular function and reduction in BNP confirm 
the beneficial effect of V on the progression of CHF. Thus, V can be considered a valid 
alternative to ACE-i in pts who cannot be treated with these recommended drugs. 
V (n=185) P (n=181) p 
All-cause deaths % 17.3 27.1 0.02 
Morbidity % 24.9 42.5 0.0002 
HF Hospitalizations % 27.6 64.6 0.01 
EF % 4:66+/-9.19 1,68+/-8.01 0.0004 
BNP pg/mL -53+/-166 64+/-337 0.0004 
SBP mmHg -8.1+/-1.2 -3.2+/-1.2 0.004 
5:15 p.m. 
839-6 Benef ic ia l  Ef fects  of  Spironolactone Are Independent of  
Baseline Aldostarone Levels in Severe Congestive 
Heart Failure: Results From the RALES Neurohormonal 
Substudy 
Michel F. Rousseau. Annie R. Robert, Jean Marie Ketelslegers, Sylvie A. Ahn, Hubert G. 
Pouleur, University of Louvain, Brussels, Belgium. 
Background : Spironolactone (spiro), an aldosterone (aldo) receptor antagonist, is 
known to improve survival in severe congestive heart failure. 
Methods : To determine if this beneficial effect was also present in patients with low 
baseline aldo plasma levels, aide plasma concentrations (normal value:<0.4nmol/mL) 
were measured in 125 patients (mean EF:25%,NYHA Ill-iV, all treated with ACE-Inibi- 
tots), randomly assigned to spiro (n=61) and placebo (n=64) in the RALES Trial. 
Results : After 24 months of follow-up, 25% of spiro patients had died versus 42% of pta- 
cebo patients (p<0.05). Further, when patients were divided according to baseline aldo 
levels _> to median (0.38nmol/mL), the benefit of spiro was present in all patients regard- 
less of baseline values (see table). Indeed, although overall mortality tended to be higher 
in placebo patients with high baseline values (49%) than those with low baseline values 
(34%), mortality was also higher in the two placebo groups when compared to patients 
treated with spiro (RR for placebo vs spiro : 1,76 [0.85-3.93] and 1.58 [0.63-4.13], [95% 
CI] for high and low baseline values respectively). Given the 95% CI ovedap, these RR 
indicate comparable risk reduction in both spiro groups. 
Conclusions : the beneficial effects of spire on survival are not limited to patients with 
high circulating aldo levels at baseline, suggesting that tissue concentration might play a 
key role in the pathophysiology of congestive heart failure. 
Splronolactone Placebo 
Death Alive Death Alive 
20.38 n=8 n=21 n=17 n=18 
<0.38 n=7 n=25 n=10 n=19 
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Alcohol septal ablation for hypertrophic obstructive cardiomyopathy has been introduced 
in the US by our group at Baylor College of Medicine in Nov 1996. The purpose of this 
abstract is to report on the clinical and echcoardiographic long-term outcome of the 219 
patients treated at our institution. The mean age was 51+/-15 years, 133 patients were 
males. The peak CK post ablation rose to 1352+/-915 units. The mean resting gradient 
decreased from 60 +/-36 mm Hg to 19+/-28 at 6 weeks and continued to decrease at one 
year to 10+/- 19 mmHg and 5+/-10 mmHg at 3 years. The provoked gradients decreased 
from 94+/-54 mm Hg to 53+/-65, 42+/-37, and 29+/-36 at 6 weeks, one year and three 
years. Along with these positive results, the septal thickness decreased from 2.07+/-0.5 
cm at baseline to 1.6 +/-0,4, 1.3+/-0.4, and 1.2+/-0.4 cm at 6weeks, one year and three 
years. 
NYHA class symptoms for heart failure decreased from 2.7+/- 0.7 to 0.3+/- at 0.6 at 3 
years. Twenty-four patients had a redo procedure within 4 months of the initial ablation 
for residual gradient, symptoms or both. One patient had a second redo for the same rea- 
sons. Ten patients underwent myomectomies for failure of the ablation procedure to 
relieve their symptoms significantly. Nine out of these ten patients had very small septal 
arteries that supplied only a limited territory of the hypertrophied septum, as evidenced 
by the smaller enzyme peak (443+/-354)in these patients. Nine patients died on follow- 
up, One patinet died after open heart surgery for failed ablation, Two patients had unwit- 
